KITLG and colorectal carcinoma: Indicative of previous findings and our present data, we suggested that p53, E2F1, miR-34c and SCF could make up a regulatory mesh-work allowing fine tuning of their responses (Figure 8) and these molecules could be promising therapeutic targets for CRC patients even those who have lost p53 function due to mutations.